TACE plus sorafenib for the treatment of hepatocellular carcinoma: Results of the multicenter, phase II SOCRATES trial

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 5, 2014, Pages 947-954

  Erhardt, Andreas ^a   Kolligs, Frank ^b   Dollinger, Matthias ^c   Schott, Eckart ^d   Wege, Hennig ^e   Bitzer, Michael ^f   Gog, Christiane ^g   Lammert, Frank ^h   Schuchmann, Markus ⁱ   Walter, Clemens ^a   Blondin, Dirk ^a   Ohmann, Christian ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; ERLOTINIB; IODINATED POPPYSEED OIL; POLYVINYL ALCOHOL; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; ETHIODIZED OIL; NICOTINAMIDE;

ADULT; AGED; ALOPECIA; ANGINA PECTORIS; ARTICLE; ASCITES; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEPATIC ENCEPHALOPATHY; HOARSENESS; HUMAN; KIDNEY FAILURE; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER METASTASIS; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DOXORUBICIN; ETHIODIZED OIL; FATIGUE; HEPATIC ENCEPHALOPATHY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84919767631     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2568-8     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538
3. Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485-1491
4. Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989-5005
5. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020-1022
6. E- EORTC (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908-943
7. Cabibbo G, Latteri F, Antonucci M, Craxi A (2009) Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 6:159-169
8. Qu XD, Chen CS, Wang JH et al (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma. BMC Cancer 12:263
9. Pawlik TM, Reyes DK, Cosgrove D et al (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29:3960-3967
10. Lencioni R, Llovet JM, Han G et al (2012) Sorafenib (S) or placebo (P) in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate- stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind, placebo-controlled SPACE trial. J Clin Oncol 30:LBA 154
11. Sansonno D, Lauletta G, Russi S et al (2012) Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 17:359-366
12. Pinter M, Hucke F, Graziadei I et al (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263:590-599
13. Park JW, Koh YH, Kim HB et al (2012) Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 56:1336-1342
14. Dufour JF, Hoppe H, Heim MH et al (2010) Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15:1198-1204
15. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307
16. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10:2878-2882
17. Abou-Alfa GK, Johnson P, Knox JJ et al (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304:2154-2160
18. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236
19. Wakabayashi I, Groschner K (2003) Vascular actions of anthracycline antibiotics. Curr Med Chem 10:427-436
20. Nexavar summary of product characteristics. http://wwwema europaeu/docs/en-GB/document-library/EPAR---Product-Information/human/000690/WC500027704pdf. Accessed October 2012
21. Fu QH, Zhang Q, Bai XL et al (2014) Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 140:1429-1440
22. Liu L, Chen H, Wang M et al (2014) Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS ONE 9:e91124
23. Kudo M, Imanaka K, Chida N et al (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47:2117-2127
24. Hsu C, Po Ching L, Morita S, Hu FC, Cheng AL (2012) Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy. Liver Cancer 1:168-176
25. Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41-52
26. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
27. Bruix J, Raoul JL, Sherman M et al (2009) Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of SHARP trial based on Barcelona Clinic Liver Cancer (BCLC) stage. J Hepatol 50:S29 (Abstract 67)
28. Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739
29. Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030-1047
30. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25